The projected trajectory of the global blow fill seal technology market foresees an estimated value of USD 3,246.7 million in 2023, poised to surge to an impressive USD 6,206.5 million by 2033. This upward trend signifies a robust sales revenue expansion, anticipating a notable CAGR of 6.8% throughout the forecast period.
The burgeoning pharmaceutical industry, coupled with manufacturers increasingly embracing advanced sterilization technologies like blow fill seal (BFS), is set to propel the global market forward. The adoption of BFS addresses concerns related to human intervention and mitigates the risks of drug contamination during the filling and packaging processes.
This technology presents a myriad of advantages, including packaging flexibility, reduced operating costs, high-level sterility assurance, minimal space and component inventory requirements, as well as a limited workforce necessity. These attributes collectively position BFS as an ideal technology for pharmaceutical companies engaged in drug packaging applications.
Get the Complete Story—Read More About Our Latest Report!
The latest generation of aseptic blow-fill-seal technology machines is specifically dedicated to a whole new range of adapted insertion applications. These modular insertion isolators are typically located outside the categorized machine room, separate from but directly connected to the B/F/S unit through a transfer tunnel.
The isolator and tunnel are typically sterilized with vaporized hydrogen peroxide, and the Class 100 environment within it is maintained by HEPA filtration. This new addition to the aseptic B/F/S system has not only streamlined the insertion process but has also provided a higher level of sterility assurance for products with tips-and-caps and rubber/silicone stoppers inserted under aseptic conditions.
This technology was introduced by Rommelag, incorporating insertion with blow-fill-seal, resulting in an advanced blow-fill-insert-seal technology. During the insertion process, either a preservative-free multi-dose system or a micro-brittle applicator could be inserted according to the requirements.
“Unit dosage packaging, such as prefilled syringes, is in high demand. This, in turn, is spurring the demand for blow-fill-seal technology in the global market. In response to this market dynamic, pharmaceutical companies are strategically integrating BFS technology into their manufacturing processes to meet the escalating demand for unit dose packaging.”- Says Future Market Insights.
Key Takeaways from the Global Blow Fill Seal Technology Market
- Prefilled syringes and injectable lead the global BFS technology market, capturing half of the value share and are anticipated to increase by 340 BPS points during the forecast period. Ampoules are growing at a CAGR of 6.4% and are expected to gain 1/5th of the market share by the end of 2033. Bottles will gain incremental opportunities worth USD 507.8 million by the end of the forecast years.
- Polyethylene is dominating the market, gaining more than 61% of the market share in 2023, creating an incremental growth opportunity of USD 2,013.4 million by the end of 2033. Polypropylene is anticipated to record 6.5% during 2023-2033, with an expansion rate of 1.9 times its current market value.
- The pharmaceutical industry is the prominent user of BFS technology, with 97% of the market share driven by rapid expansion. In the pharmaceutical industry, respiratory is anticipated to generate 1,202.4 million incremental growth opportunities during the forecast years. Food and beverage are expected to expand 1.8 times its current market value in the upcoming years.
Global Blow Fill Seal Technology Market Landscape
Unither Pharmaceuticals SAS, Rommelag SE & Co. KG, Woodstock Sterile Solutions, Curida AS, New Vision Pharmaceuticals LLC, Weiler Engineering Inc, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Nephron Pharmaceuticals Corporation, Horizon Pharmaceuticals Inc, are some of the noticeable players in the market. The tier 1 players in the market hold 10–15% of the overall blow fill seal technology market including GlaxoSmithKline plc, Takeda Pharmaceuticals International AG, and Horizon Pharmaceuticals Plc.
Key Developments
- In December 2021, Woodstock secured a United States patent for their cold blow fill seal system. This innovative approach involves meticulous temperature control to prevent heat-related damage. It is particularly suitable for medications susceptible to temperature-induced degradation.
- In January 2021, Berry Global Healthcare introduced Cyrano, their latest blow-fill-seal closure, renowned for its lightweight design. Tailored to minimize plastic usage, Cyrano serves as an accessible solution for various intravenous and infusion systems.
Global Blow fill Seal Technology Market by Category
By Product:
- Bottles
- 0.2–100ml
- 100–500ml
- Above 500 ml
- Ampoules
- 0.1–10ml
- 10–100ml
- Vials
- 0.1–10ml
- 10–50ml
- Others (Prefilled Syringes Cartridges & Injectable)
By Material:
- PE
- LDPE
- HDPE
- PP
- Others (EVOH etc.)
By End Use:
- Pharmaceuticals
- Ophthalmic
- Injectable
- Biologics
- Wound care
- Respiratory Therapy
- Food & Beverage(incl. Nutraceuticals)
- Cosmetics and Personal Care
- Others (Chemicals etc.)
By Region:
- North America
- Latin America
- Asia Pacific Excluding Japan
- Western Europe
- Eastern Europe
- Middle East and Africa
- Japan
